News Archive

Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.

Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.

Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.

As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.

European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.

Novartis joins seven global companies to found the Value Balancing Alliance